Contemporary breast cancer treatment-associated venous thromboembolism

 

by Emma L. Blower, Cliona C. Kirwan

 

Breast cancer patients have a three-to four fold increased risk of venous thromboembolism (VTE) when compared to women of an equivalent age without cancer[1], equating to approximately 1-2% of all breast cancer patients[2]. More importantly, breast cancer treatment, in particular surgery, chemotherapy and endocrine therapy, significantly escalates this risk further[3]. VTE is known to be associated with both disease recurrence and reduced survival[4–6], but in itself is a devastating complication[6]. Breast cancer treatment-associated VTE rates have dramatically risen over the last couple of decades [7]. This is potentially due to the increased diagnosis of asymptomatic VTE secondary to the enhanced sensitivity of imaging techniques for cancer staging; more aggressive cancer therapies; or a combination of both[1]. This increased rate has led to a magnified awareness of cancer treatment-associated VTE than previously seen[8], yet the optimal thromboprophylaxis mechanism, particularly for patients undergoing surgery, is not entirely clear[9].

The reported incidence of VTE following breast surgery for malignancy ranges from 0.16-0.4%. It is higher for mastectomy, with or without reconstruction, than for breast conserving surgery (BCS)[10–13]. A retrospective cohort study of 13,202 patients reported that surgery, in the form of mastectomy or BCS, increased the rate of VTE (HR 2.2) as compared to those not undergoing surgery, but only in the first month after discharge[7]. However, in the Million Women Study, for women undergoing surgery for cancer, the risk of VTE remained elevated for at least 12 weeks post-cancer surgery[14], with a relative risk at 6 weeks of 92, falling to 53 at 12 weeks and 6 at 1 year[14]. A recent American College of Surgeons National Surgical Quality Improvement Programme analysis reported an overall VTE incidence within 30 days of surgery to be 0.13% for BCS, 0.29% for mastectomy alone, 0.41% for delayed reconstruction and 0.52% for mastectomy with reconstruction[10]. These findings were similar to Momeni et al[15] who reported rates of 0.47% for BCS, 0.59% for mastectomy alone, 0.33% with mastectomy and implant reconstruction and 0.71% for mastectomy with autologous reconstruction[15]. Delayed autologous reconstruction after mastectomy has been reported to be associated with even higher VTE rates. The VTE rate was 4% in one study despite thromboprophylaxis[16] and 31.4% in the absence of thromboprophylaxis in a smaller study[17].

The current American College of Chest Physicians (ACCP) recommendations for breast surgery in relation to VTE are detailed within the general surgery section of the document[18]. Mastectomy is considered low risk for VTE, but age >60 and operation time  2 hours are identified as patient-specific risk factors, and commonly apply to breast surgery patients[18]. Given the lack of evidence for the risk-benefit profile of chemoprophylaxis, the American Society of Breast Surgeons consensus statement supports an individualised risk assessment strategy[19], as does the National Institute for Health and Care Excellence in the United Kingdom[20]. The Caprini score, stratifies the risk of VTE in surgical patients[21]. In a study of 522 consecutive mastectomy patients (67% of whom underwent immediate implant-based reconstruction), 83% had a Caprini score of 5-7, and were therefore recommended preoperative chemoprevention, that was then continued postoperatively until discharge. VTE and haematoma rates were both low at 0.2% and 3.4% respectively. However, compliance with chemoprevention was only 60%. Interestingly, the American Society of Breast Surgeons consensus statement, which has been adopted by the Association of Breast Surgery in the UK, support early ambulation and mechanical VTE prophylaxis in the majority of breast surgery patients[19,22].

The increased VTE risk with chemotherapy has been confirmed in two retrospective cohort studies[7,23] and one prospective study[24]. Walker et al[7] presented an adjusted hazard ratio (HR) of 2.2 in those receiving chemotherapy as compared to those not, and Brand et al[23] stated a HR of 1.8. This increased risk was most significant during chemotherapy (HR 10.8) and for the first month after therapy cessation (HR 8.4), although some increased risk remained up to three months after the cessation of therapy before returning to baseline[7]. In a prospective study of breast cancer chemotherapy patients undergoing duplex ultrasound screening, VTE was diagnosed in 17% of those with advanced breast cancer and 8% of those with early breast cancer[24]. The majority of these events occurred within 3 months of chemotherapy[27,4]. Although chemotherapy induces vascular endothelial cell activation, this does not appear to be the primary mechanism for chemotherapy-induced VTE[25].Chemotherapy-induced apoptosis may enhance hypercoagulability and initiate VTE[25]. Central-venous catheters are frequently required in breast cancer patients receiving chemotherapy, and are associated with a doppler ultrasound detected VTE cumulative probability of 9.6% at 3 months and 11.5% at 6 months, with 20% being symptomatic[26]

Endocrine therapy can enhance prothrombotic tendency independent of other treatments[27]. In two retrospective cohort studies, endocrine therapy was found to increase the risk of VTE during the first three month [7,28]. Walker et al reported a doubling in VTE risk, with this risk being increased five-fold in the first three months of treatment[7]. Blom et al reported a 1.8 times increased risk in those without distant metastases and a 1.3 times increased risk in those with metastases (28). In the former study, the risk of VTE was attributable to tamoxifen only, with no increased risk associated with Aromatase Inhibitors (AIs)[7]. This is consistent with Xu et al who reported a 41% lower VTE risk with AIs as compared to tamoxifen[29]. Interestingly, in patients who underwent delayed breast reconstruction including free and pedicled flaps, fat grafting and tissue expander/ implant based reconstructions; there was no difference in VTE rate between those on endocrine therapy (including, tamoxifen, AIs and fulvestrant) and those not[30,31]. The increased VTE risk with tamoxifen is also applicable to male breast cancer patients[32]. In a study of 218 male patients with early breast cancer, 97.7% were oestrogen receptor positive and received tamoxifen therapy[32]. The cumulative VTE risk was 11.9%, with 80% of these events occurring within the first 18 months after the initiation of treatment[32].

In conclusion, breast cancer treatment-associated VTE is more frequently diagnosed due to modern breast cancer management techniques; particularly the advent of complex microvascular free-flap breast reconstructions, more aggressive chemotherapy regimens and improved cancer staging images. Awareness among clinicians of this risk is imperative in ensuring appropriate thromboprophylaxis, that balances the risk of chemoprophylaxis with VTE associated morbidity and mortality.


REFERENCES

  1. Walker AJ, Card TR, West J, Crooks C, Grainge MJ. Incidence of venous thromboembolism in patients with cancer – A cohort study using linked United Kingdom databases. Eur J Cancer. 2013 Apr;49(6):1404–13.
  2. Chew HK, Wun T, Harvey DJ, Zhou H, White RH. Incidence of Venous Thromboembolism and the Impact on Survival in Breast Cancer Patients. J Clin Oncol. 2006 Jan 20;25(1):70–6.
  3. Horsted F, West J, Grainge MJ. Risk of Venous Thromboembolism in Patients with Cancer: A Systematic Review and Meta-Analysis. Cannegieter SC, editor. PLoS Med. 2012 Jul 31;9(7):e1001275.
  4. von Tempelhoff G-F, Schönmann N, Heilmann L. Thrombosis--a clue of poor prognosis in primary non-metastatic breast cancer? Breast Cancer Res Treat. 2002 Jun;73(3):275–7.
  5. Sørensen HT, Mellemkjær L, Olsen JH, Baron JA. Prognosis of Cancers Associated with Venous Thromboembolism. N Engl J Med. 2000 Dec 21;343(25):1846–50.
  6. Khan UT, Walker AJ, Baig S, Card TR, Kirwan CC, Grainge MJ. Venous thromboembolism and mortality in breast cancer: cohort study with systematic review and meta-analysis. BMC Cancer. 2017 Dec 10;17(1):747.
  7. Walker AJ, West J, Card TR, Crooks C, Kirwan CC, Grainge MJ. When are breast cancer patients at highest risk of venous thromboembolism? A cohort study using English health care data. Blood. 2016 Feb 18;127(7):849–57; quiz 953.
  8. Kirwan CC. Prophylaxis for venous thromboembolism during treatment for cancer: questionnaire survey. Bmj. 2003;327(7415):597–8.
  9. Patiar S, Kirwan CC, McDowell G, Bundred NJ, McCollum CN, Byrne GJ. Prevention of venous thromboembolism in surgical patients with breast cancer. Br J Surg. 2007 Apr;94(4):412–20.
  10. Nwaogu I, Yan Y, Margenthaler JA, Myckatyn TM. Venous Thromboembolism after Breast Reconstruction in Patients Undergoing Breast Surgery: An American College of Surgeons NSQIP Analysis. J Am Coll Surg. 2015 May;220(5):886–93.
  11. Fischer JP, Wes AM, Tuggle CT, Wu LC. Venous Thromboembolism Risk in Mastectomy and Immediate Breast Reconstruction. Plast Reconstr Surg. 2014 Mar;133(3):263e-273e.
  12. Tran BH, JoAnna Nguyen T, Hwang BH, Vidar EN, Davis GB, Chan LS, et al. Risk factors associated with venous thromboembolism in 49,028 mastectomy patients. The Breast. 2013 Aug;22(4):444–8.
  13. Andtbacka RHI, Babiera G, Singletary SE, Hunt KK, Meric-Bernstam F, Feig BW, et al. Incidence and prevention of venous thromboembolism in patients undergoing breast cancer surgery and treated according to clinical pathways. Ann Surg. 2006 Jan;243(1):96–101.
  14. Sweetland S, Green J, Liu B, Berrington de Gonzalez A, Canonico M, Reeves G, et al. Duration and magnitude of the postoperative risk of venous thromboembolism in middle aged women: prospective cohort study. BMJ. 2009 Dec 3;339(dec03 1):b4583–b4583.
  15. Momeni A, Fox JP. Venous Thromboembolism After Surgical Treatment of Breast Cancer. Ann Plast Surg. 2017 Oct;80(2):1.
  16. Enajat M, Damen THC, Geenen A, Timman R, van der Hulst RRWJ, Mureau MAM. Pulmonary Embolism after Abdominal Flap Breast Reconstruction. Plast Reconstr Surg. 2013 Jun;131(6):1213–22.
  17. Konoeda H, Yamaki T, Hamahata A, Ochi M, Osada A, Hasegawa Y, et al. Incidence of deep vein thrombosis in patients undergoing breast reconstruction with autologous tissue transfer. Phlebol J Venous Dis. 2017 May 19;32(4):282–8.
  18. Gould MK, Garcia DA, Wren SM, Karanicolas PJ, Arcelus JI, Heit JA, et al. Prevention of VTE in Nonorthopedic Surgical Patients. Chest. 2012 Feb;141(2):e227S-e277S.
  19. American Society of Breast Surgeons T. Consensus Guideline on Venous Thromboembolism (VTE) Prophylaxis for Patients Undergoing Breast Operations.
  20. Venous thromboembolism in over 16s. 2017.
  21. Laws A, Anderson K, Hu J, McLean K, Novak L, Dominici LS, et al. Implementation of a Venous Thromboembolism Prophylaxis Protocol Using the Caprini Risk Assessment Model in Patients Undergoing Mastectomy. Ann Surg Oncol. 2018;25(12):3548–55.
  22. Association of Breast Surgery. Guidance Platform. [Internet]. [cited 2019 May 12]. Available from: https://associationofbreastsurgery.org.uk/media/64336/breast-surgery-v1.pdf
  23. Brand JS, Hedayati E, Humphreys K, Ludvigsson JF, Johansson ALV, Bergh J, et al. Chemotherapy, genetic susceptibility, and risk of venous thromboembolism in breast cancer patients. Clin Cancer Res. 2016;22(21):5249–55.
  24. Kirwan CC, McDowell G, McCollum CN, Byrne GJ. Incidence of venous thromboembolism during chemotherapy for breast cancer: impact on cancer outcome. Anticancer Res. 2011 Jun 1;31(6):2383–8.
  25. Kirwan CC, Mccollum CN, Mcdowell G, Byrne GJ. Investigation of Proposed Mechanisms of Chemotherapy-Induced Venous Thromboembolism: Endothelial Cell Activation and Procoagulant Release Due to Apoptosis. Clin Appl Thromb. 2015;21(5):420–7.
  26. Debourdeau P, Espié M, Chevret S, Gligorov J, Elias A, Dupré PF, et al. Incidence, risk factors, and outcomes of central venous catheter-related thromboembolism in breast cancer patients: the CAVECCAS study. Cancer Med. 2017;6(11):2732–44.
  27. Deitcher SR, Gomes MP V. The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma. Cancer. 2004 Aug 1;101(3):439–49.
  28. BLOM JW, VANDERSCHOOT JPM, OOSTINDIER MJ, OSANTO S, VAN DER MEER FJM, ROSENDAAL FR. Incidence of venous thrombosis in a large cohort of 66 329 cancer patients: results of a record linkage study. J Thromb Haemost. 2006 Mar 1;4(3):529–35.
  29. Xu X, Chlebowski RT, Shi J, Barac A, Haque R. Aromatase inhibitor and tamoxifen use and the risk of venous thromboembolism in breast cancer survivors. Breast Cancer Res Treat. 2019;174(3):785–94.
  30. Billon R, Bosc R, Belkacemi Y, Assaf E, SidAhmed-Mezi M, Hersant B, et al. Impact of adjuvant anti-estrogen therapies (tamoxifen and aromatase inhibitors) on perioperative outcomes of breast reconstruction. J Plast Reconstr Aesthetic Surg. 2017;70(11):1495–504.
  31. Tran BNN, Ruan QZ, Cohen JB, Kamali P, Doval AF, Tobias AM, et al. Does Hormone Therapy Use Increase Perioperative Complications in Abdominally Based Microsurgical Breast Reconstruction? Plast Reconstr Surg. 2018 Jun;141(6):805e-813e.
  32. Eggemann H, Bernreiter AL, Reinisch M, Loibl S, Taran FA, Costa SD, et al. Tamoxifen treatment for male breast cancer and risk of thromboembolism: prospective cohort analysis. Br J Cancer. 2019;120(3):301–5.
  • Cliona Kirwan

    Cliona Kirwan

    NIHR Clinician Scientist In Surgical Oncology and Consultant Oncoplastic Breast Surgeon Division of Molecular and Clinical Cancer Sciences, School of Medical sciences, Faculty of Biology, Medicine and Health, University of Manchester
    view profile
  • Emma Blower

    Emma Blower

    Phd Student at Cancer Research UK, Manchester Institute, Manchester
    view profile

Rate this article

Login or register to leave a comment or rate this article


Register